Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Gil

Showing results (151-160 of 217) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyJavier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
The American Journal of Cardiology|November 3, 2004
Short-term (28 days) prognosis between genders according to the type of coronary event (Q-wave versus non-Q-wave acute myocardial infarction versus unstable angina pectoris)Jaume Marrugat, María García, Roberto Elosua, et al.
Archives of Endocrinology and Metabolism|June 20, 2020
Elevated leptin levels in healthy climacteric women from Northeastern Brazil: an effect of age or adiposity?Ana Cyntia B N Maniçoba, Clariano P Oliveira Neto, Johnny R Nascimento, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2015
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) studyMiguel Martín, Sibylle Loibl, Gunter von Minckwitz, et al.
Plos One|February 24, 2015
Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database studyMarietta Rottenkolber, Eef Voogd, Liset van Dijk, et al.
Cancers|April 26, 2025
Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d'Oncologia Breast Cancer Observational Cohort StudyHelena Pla, Bartomeu Fullana, Anna Esteve, et al.
Breast Cancer Research : BCR|May 26, 2026
Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studiesSonia Servitja, Eva Carrasco, Raquel Andrés, et al.
Biomedicines|April 9, 2020
Dietary Supplementation with Chestnut (Castanea sativa) Reduces Abdominal Adiposity in FVB/n Mice: A Preliminary StudyPedro Rodrigues, Tiago Ferreira, Elisabete Nascimento-Gonçalves, et al.
International Journal of Molecular Sciences|August 14, 2019
The Cyclooxigenase-2 Inhibitor Parecoxib Prevents Epidermal Dysplasia in HPV16-Transgenic Mice: Efficacy and Safety ObservationsTiago Ferreira, Sandra Campos, Mónica G Silva, et al.
Pageof 22

Showing results (151-160 of 217) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyJavier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
The American Journal of Cardiology|November 3, 2004
Short-term (28 days) prognosis between genders according to the type of coronary event (Q-wave versus non-Q-wave acute myocardial infarction versus unstable angina pectoris)Jaume Marrugat, María García, Roberto Elosua, et al.
Archives of Endocrinology and Metabolism|June 20, 2020
Elevated leptin levels in healthy climacteric women from Northeastern Brazil: an effect of age or adiposity?Ana Cyntia B N Maniçoba, Clariano P Oliveira Neto, Johnny R Nascimento, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2015
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) studyMiguel Martín, Sibylle Loibl, Gunter von Minckwitz, et al.
Plos One|February 24, 2015
Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database studyMarietta Rottenkolber, Eef Voogd, Liset van Dijk, et al.
Cancers|April 26, 2025
Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d'Oncologia Breast Cancer Observational Cohort StudyHelena Pla, Bartomeu Fullana, Anna Esteve, et al.
Breast Cancer Research : BCR|May 26, 2026
Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studiesSonia Servitja, Eva Carrasco, Raquel Andrés, et al.
Biomedicines|April 9, 2020
Dietary Supplementation with Chestnut (Castanea sativa) Reduces Abdominal Adiposity in FVB/n Mice: A Preliminary StudyPedro Rodrigues, Tiago Ferreira, Elisabete Nascimento-Gonçalves, et al.
International Journal of Molecular Sciences|August 14, 2019
The Cyclooxigenase-2 Inhibitor Parecoxib Prevents Epidermal Dysplasia in HPV16-Transgenic Mice: Efficacy and Safety ObservationsTiago Ferreira, Sandra Campos, Mónica G Silva, et al.
Pageof 22